Home  |  Contact

UniProtKB/Swiss-Prot Q99836: Variant p.Ile207Thr

Myeloid differentiation primary response protein MyD88
Gene: MYD88
Variant information

Variant position:  207
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Isoleucine (I) to Threonine (T) at position 207 (I207T, p.Ile207Thr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (I) to medium size and polar (T)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  Found in hematological malignancies; somatic mutation; unknown pathological significance.
Any additional useful information about the variant.



Sequence information

Variant position:  207
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  296
The length of the canonical sequence.

Location on the sequence:   YRLKLCVSDRDVLPGTCVWS  I ASELIEKRCRRMVVVVSDDY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Gorilla                       YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Rhesus macaque                YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Chimpanzee                    YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Mouse                         YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Rat                           YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Pig                           YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDY

Bovine                        YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDEY

Sheep                         YRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDXY

Chicken                       FKLKLCVFDRDVLPGTCVWSISGELIERRCRRMVVVISDDY

Xenopus tropicalis            YKLKLCVFDRDVLPGTCLWSITSELIEHRCRKMVVIISDDY

Zebrafish                     YNLKLCVFDRDVLPGTCVWTIASELIEKRCKRMVVVISDDY

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 296 Myeloid differentiation primary response protein MyD88
Domain 159 – 296 TIR
Alternative sequence 156 – 296 HMPERFDAFICYCPSDIQFVQEMIRQLEQTNYRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDYLQSKECDFQTKFALSLSPGAHQKRLIPIKYKAMKKEFPSILRFITVCDYTNPCTKSWFWTRLAKALSLP -> AAGWWWLSLMITCRARNVTSRPNLHSASLQVPIRSD. In isoform 3 and isoform 4.
Alternative sequence 215 – 215 R -> RLARRPRGG. In isoform 6.
Mutagenesis 196 – 196 R -> A. Reduced interaction with TIRAP, and strongly reduced activity. Strongly reduced interaction with TIRAP; when associated with A-288.
Mutagenesis 197 – 197 D -> A. Slightly reduced activity.
Mutagenesis 217 – 217 R -> A. Strongly reduced activity.


Literature citations

Oncogenically active MYD88 mutations in human lymphoma.
Ngo V.N.; Young R.M.; Schmitz R.; Jhavar S.; Xiao W.; Lim K.H.; Kohlhammer H.; Xu W.; Yang Y.; Zhao H.; Shaffer A.L.; Romesser P.; Wright G.; Powell J.; Rosenwald A.; Muller-Hermelink H.K.; Ott G.; Gascoyne R.D.; Connors J.M.; Rimsza L.M.; Campo E.; Jaffe E.S.; Delabie J.; Smeland E.B.; Fisher R.I.; Braziel R.M.; Tubbs R.R.; Cook J.R.; Weisenburger D.D.; Chan W.C.; Staudt L.M.;
Nature 470:115-119(2011)
Cited for: INTERACTION WITH IRAK4; VARIANTS MET-39; GLY-136; ILE-136; PHE-204; ARG-205; CYS-206; THR-207; ARG-209; THR-219; ASN-230; PRO-252 AND PRO-281; CHARACTERIZATION OF VARIANTS ARG-209; THR-219; ASN-230; PRO-252 AND PRO-281;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.